Eplontersen Drug Asset Due Diligence Report 2026

This Eplontersen Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Eplontersen can convert its ASO profile and TTR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Eplontersen (query alias: eplontersen)
Modality / target	ASO; TTR; TTR inhibitors
Highest global status	Approved
Originator	Ionis Pharmaceuticals, Inc.
Active developers	AstraZeneca PLC, Ionis Pharmaceuticals, Inc., AstraZeneca Pty Ltd.

The MCP disease footprint includes Amyloidosis, Hereditary, Transthyretin-Related, Transthyretin-related (ATTR) familial amyloid polyneuropathy, Transthyretin Amyloid Cardiomyopathy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05667493	Phase 3	Enrolling by invitation	1400	Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
NCT06194825	Phase 3	Active, not recruiting	64	Percent change of serum TTR concentration from baseline
NCT07608354	Phase 2	Active, not recruiting	326	Cardiopulmonary exercise test peak VO2

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Phase 3; n=168; evaluation: not stated. Reported fields: Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 66(Least Squares Mean): Difference in LS Mean = -24.7593(95% CI, -30.9552 to -18.5635), P-Value = 0.00000001; Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 66(Least Squares Mean) = 25.0557 scores on a scale (Standard Error, 2.3874); Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 66(Least Squares Mean) = 0.2964 scores on a scale (Standard Error, 2.4123)

FDA-Approved Drugs-WAINUA-CLINICAL STUDIES

Phase 2/3; n=204; evaluation: Positive. Reported fields: mNIS+7(Week 35) = 9.2 point (SE, 1.9); mNIS+7(Week 35) = 0.2 point (SE, 1.9)

Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy

Phase 3; n=not disclosed; evaluation: not stated. Reported fields: Adverse Event: Adverse events = Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group. ; Adverse Event: Adverse events = Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Eplontersen addresses Amyloidosis, Hereditary, Transthyretin-Related, Transthyretin-related (ATTR) familial amyloid polyneuropathy, Transthyretin Amyloid Cardiomyopathy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—ASO—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-12-06	AstraZeneca and Ionis sign deal to develop and commercialise eplontersen	Phase 3	Financial terms not disclosed
2018-04-17	Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR	Not disclosed	US$2,005.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO